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Available online xxxxNeuropeptide Y (NPY)-Y2 receptors are G-protein coupled receptors and, upon activation, induce opening of po-
tassium channels or closing of calcium channels. They are generally presynaptically located. Depending on the
neuron inwhich they are expressed they mediate inhibition of release of NPY and of the neuron's classical trans-
mitter GABA, glutamate or noradrenaline, respectively. Here we provide evidence that Y2 receptor binding is
inhibited dose-dependently by GTPγS along Schaffer collaterals, the stria terminalis and the ﬁmbria indicating
that Y2 receptors are functionally coupled to G-proteins along these ﬁber tracts. Double immune ﬂuorescence re-
vealed coexistence of Y2-immunoreactivity with β-tubulin, a marker for axons in the stria terminalis, but not
with synaptophysin labeling presynaptic terminals, supporting the localization of Y2 receptors along axonal
tracts. After kainic acid-induced seizures in rats, GTPγS-induced inhibition of Y2 receptor binding is facilitated
in the Schaffer collaterals but not in the stria terminalis. Our data indicate that Y2 receptors are not only located
at nerve terminals but also along ﬁber tracts and are there functionally coupled to G-proteins.










Neuropeptide Y (NPY) is amember of a family of 36 amino acid pep-
tides that also includes pancreatic polypeptide (PP) and peptide YY
(PYY). While PYY and PP are primarily found in the intestine and pan-
creas, respectively, NPY is widely distributed throughout the peripheral
and central nervous systems (Hokfelt et al., 1998). In the brain it is one
of the most abundant neuropeptides, mainly contained in subclasses of
GABA-ergic and, to a lesser extent, in noradrenergic neurons.
Established actions in the central nervous system include its participa-
tion in regulation of feeding and drinking and integration of emotions
such as anxiety and depression, and NPY may exert endogenous anti-
convulsive/neuroprotective functions (Vezzani and Sperk, 2004; Tasan
et al., 2016). Among the presently established NPY receptors (Y1, Y2,
Y4 and Y5), Y1 and Y2 receptors are most abundant in the brain
(Blomqvist and Herzog, 1997). Whereas Y1 receptors are postsynaptic
receptors, Y2 receptors are primarily presynaptically located and medi-
ate inhibition of neurotransmitter release (Greber et al., 1994; Klapstein, sabine.fuertinger@gmx.at
medizin, Bezirkskrankenhaus
6250 Kundl, Austria.
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/j.npep.2016.10.005and Colmers, 1997). Both receptors are coupled to G-proteins and may
act through activation of potassium channels or inhibition of calcium
channels (Ewald et al., 1989). The localization of these receptors can
be shown by receptor autoradiography using radiolabeled Leu31,
Pro34-PYY, or PYY3–36 as Y1- and Y2-selective ligands, respectively
(Dumont et al., 1996). To analyze functional coupling of a ligand to its
G-protein coupled receptor, activation of GTPγS binding by the receptor
ligand (Weiland and Jakobs, 1994; Shaw et al., 2003) as well as, in con-
trary, modulation of ligand binding by GTPγS have been used (Parker
et al., 2007a; Zhen et al., 2015).
Using [125I]PYY3–36 receptor autoradiography for Y2 receptors,
prominent labeling of the strata radiatum and oriens was observed in
sectors CA1 to CA3 of the hippocampus. Immunohistochemistry for Y2
receptors and in situ hybridization for Y2 mRNA containing neurons in-
dicated that this labeling may represent axon ﬁbers of Schaffer collat-
erals arising from CA3 pyramidal cells (Stanic et al., 2006). Also other
ﬁber tracts, the ﬁmbria and the stria terminalis originating in the hippo-
campus and bed nucleus of the stria terminalis/amygdala, respectively,
are labeled by [125I]PYY3–36 (Dumont et al., 1996). This suggests that Y2
receptorsmay be expressed along these ﬁber tracts.Whether this label-
ing represents functionally coupled Y2 receptors or spare receptors, or
receptors transported to the respective axon terminal is not known. In-
terestingly, kainic acid (KA)-induced seizures are followed by a rapid in-
crease in afﬁnity of Y2 receptors in Schaffer collaterals and increased
expression in granule cells (Schwarzer et al., 1998). We now aimed tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
receptors along axonal ﬁber tracts and its relevance for epilepsy, Neu-
2 E. Dum et al. / Neuropeptides xxx (2016) xxx–xxxinvestigate whether these receptors located along neuronal ﬁber tracts
are also functionally coupled to G-proteins. We applied Y2 receptor au-
toradiography using [125I]PYY3–36 as radioligand and investigated its in-
hibition by the non-hydrolizable GTP analogue GTPγS in brain sections
from rats exposed to KA-induced seizures and in controls. Inhibition of
Y2 agonist binding by GTPγS reﬂects a shift from a high afﬁnity to a
low afﬁnity state and is an index for G-protein coupling (Parker et al.,
2007a; Zhen et al., 2015).
2. Methods
2.1. Rats and injection of kainic acid
Adult male Sprague-Dawley rats (210–260 g; Forschungsinstitut für
Versuchstierzucht, Himberg, Austria)were used. They had free access to
food andwater andwere housed at a temperature of 22–23 °C, a relative
humidity of 50–60% and a 12 h light/dark cycle. All animal experiments
were conducted according to national guidelines and European Com-
munity laws. They were approved by the Committee for Animal Protec-
tion of the Austrian Ministry of Science and care was taken to
minimize suffering of the rats.
Rats (in total 24)were injected eitherwith 10mg/kg kainic acid (KA,
Ascent Scientiﬁc Ltd., North Somerset, United Kingdom, dissolved in
0.9% NaCl at a concentration of 5 mg/ml and adjusted to pH 7.0) or
with saline. Seizure behavior was monitored for at least three hours
and rated using a 4-stage rating scale described previously (Sperk
et al., 1983). Rats with generalized seizures (rating 3 and 4) were killed
by exposure to CO2 gas after 10 days. Brains were rapidly removed from
the sculls and snap-frozen in −70 °C isopentane (Merck, Darmstadt,
Germany). Brains were cut either coronary or horizontally between
the septum and the ventral hippocampus using a cryostat-microtome.
Three subsequent sections (20 μm)were always thaw-mounted togeth-
er on silane-coated slides and then stored at−70 °C. Every 10th slide
was subjected to Nissl staining as described (Schwarzer et al., 1998).
These sections were used to identify corresponding sections from
three rats for receptor autoradiography.
2.2. Receptor autoradiography
For Y2 receptor autoradiography, PYY3–36 was radiolabeled with 125I
(2200 Ci/mmol; New England Nuclear, DuPont, Boston, USA) using the
chloramine T procedure and puriﬁed by high performance liquid chro-
matography (HPLC) as described before (Bellmann et al., 1991). The
ﬁrst radioactive peak presumably containing mono-iodinated Tyr36[125-
I]PYY was used. Receptor autoradiographies were performed as de-
scribed before (Dumont et al., 1996; Schwarzer et al., 1998). Slides
were thawed and pre-incubated for 30 min at room temperature in
200 ml of Krebs-Henseleit-Tris buffer (118 mM NaCl, 4.8 mM KCl,
1.3 mM MgSO4, 1.2 mM CaCl2, 50 mM glucose, 15 mM NaHCO3,
1.2 mM KH2PO4, 10 mM Tris, pH 7.3). The incubation was performed
in Coplin jars containing 20 ml of the same buffer supplemented with
0.1% bovine serum albumin, 0.05% bacitracin, and 25 pM [125I]PYY3–36.
Kinetic analysis of the receptor binding was performed in sections of
the dorsal hippocampus of controls and 48 h after KA injection. Incuba-
tions were done in triplicates at concentrations of 25 pM [125I]PYY3–36.
GTPγS was included at concentrations of 0, 1, 3, 10, 30 and 100 μM. In
an initial experiment the dorsal hippocampus was evaluated with the
additional concentrations of 0.03, 300 and 1000 μM of GTPγS. Incuba-
tions were performed at room temperature for 2 h. Unspeciﬁc binding
was determined in the presence of 1 μMNPY; it was uniformly distrib-
uted throughout the section and was b5% of total binding (e.g. in
Schaffer collaterals). The sections were dipped twice and then washed
for 30 s in ice-cold Krebs-Henseleit-Tris buffer, dipped in deionized
water, and rapidly dried under a stream of cold air. They were then ex-
posed to β-max ﬁlms for 10 days together with [125I]-microscales (both
Amersham, Bucks, U.K.).Please cite this article as: Dum, E., et al., Effective G-protein coupling of Y2
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The autoradiographs were developed, digitized through the
Appligene Image System (Illkirch, France), and analyzed using the pub-
lic domain NIH ImageJ program (Rasband, W.S., ImageJ, U. S. National
Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/,
1997–2016). The absorbance was measured in the strata oriens and
radiatum of CA1 representing ﬁber tracts and terminals of the Schaffer
collaterals, the septum, piriform cortex, stria terminalis, and theﬁmbria.
Absolute values were calculated by using a dose-response curve of the
absorbance obtained through concomitant autoradiography of 125I-
microscales and expressed as fmol/mg of wet tissue weight. Speciﬁc
bindingwas calculated by subtracting themean unspeciﬁc binding (de-
termined in 35 sections in the presence of 1 μMNPY) from total binding.
For studies on the inhibition of [125I]PYY3–36 binding by GTPγS, mean
values determined in three to six sections per animal were averaged.
These values were used for calculating the mean values for 3 to 5 rats.
Data are expressed as percentage of total speciﬁc [125I]PYY3–36 binding.
Statistical analysis was done for time course and displacement studies
by analysis of variance (ANOVA) and the multiple-comparison Dunnett
posteriori test.
Values of individual sections were obtained by calculating the mean
values of each hemisphere in 3 consecutive sections. Values obtained
from 3 to 4 rats were averaged and analyzed. Displacement curves for
[125I]PYY3–36 binding by GTPγS was evaluated using GraphPad Prism
program(GraphPadPrismversion 5.00 forMacOSX, GraphPad Software,
San Diego California USA, www.graphpad.com). Mean values from 3 to 4
rats (obtained asmean from 3 consecutive sections) for each GTPγS con-
centrationwere obtained and calculated in the GraphPad Prism program
(using the non-linear regression (curve ﬁt) and log inhibitor vs. response
functions). Kd values for inhibition of [125I]PYY3–36 binding by GTPγS
were determined individually for each animal. Increase in [125I]PYY3–36
binding in KA treated rats vs. controls was determined from the total
(without GTPγS) speciﬁc binding in the same sections.
2.4. Regression analysis and statistical analyses
Dose-response curves for [125I]PYY3–36 binding by GTPγS and statis-
tical analyses were performed using GraphPad Prism. Values of individ-
ual sections were obtained by calculating the mean values of each
hemisphere in 3 consecutive sections. These values, obtained from 3
to 4 rats, were averaged and analyzed using the non-linear regression
(curve ﬁt) and log inhibitor vs. response functions. IC50 values for inhi-
bition of [125I]PYY3–36 binding by GTPγS were determined individually
for each animal and then averaged (±SEM). Increase in [125I]PYY3–36
binding in KA treated rats vs. controls was determined from the total
(without GTPγS) speciﬁc binding in the same sections. For comparison
of two groups a two-tailed Student's t-test was used. All data are pre-
sented as mean ± SEM. Statistical signiﬁcance was deﬁned as p b 0.05.
2.4.1. Immunohistochemistry
Sections from the ventral hippocampus of C57BL/6 mice were used.
The brainswere perfusedwith 4% paraformaldehyde in phosphate buff-
ered saline (PBS) and 30 μm sections were cut. For immunohistochem-
istry, we used Y2 receptor antibody (1:1000, RA14112, Neuromics,
Edina, Minnesota, USA through Eubio, Vienna, Austria). It was per-
formed as described previously (Stanic et al., 2006; Wood et al., 2015).
As secondary antibody we used a horseradish peroxidase (HRP)-
coupled goat anti-rabbit antibody (1:250 P0448; Dako, Vienna,
Austria). It was ampliﬁed and detected with tyramide ﬂuorescein (TSA
ﬂuorescein, signal ampliﬁcation solution, 1:100, in-house) for ﬂuores-
cence labeling or directly developed with diamino-benzidine and
H2O2 (Wood et al., 2015). Sections were mounted on slides and exam-
ined in a ﬂuorescence microscope.
Double immunoﬂuorescence was performed for Y2 receptors to-
getherwith synaptophysin (amarker for synapses) and for Y2 receptorsreceptors along axonal ﬁber tracts and its relevance for epilepsy, Neu-
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hippocampus of WT mice and Y2 receptor knock out mice (Zambello
et al., 2011) as described previously (Wood et al., 2015). We used the
same Y2 receptor antibody (1:500) described above, a synaptophysin
antibody (S5768, 1: 1.000; Sigma, St. Louis, MO, USA) and a mouse β-
tubulin antibody (Tu-20 #4466, 1:200; Cell Signaling Technology, Dan-
vers, MA, USA). Sectionswereﬁrst incubatedwithmouse Ig blocking re-
agent (M.O.M., 1:27; Vector, Burlingame, CA, USA; 60 min at room
temperature) for blocking mouse epitopes prior to incubation with
anti-mouse antibodies. Theywere incubatedwith Y2 antibodies togeth-
er with the β-tubulin or synaptophysin antibody, respectively, at room
temperature for 24 h. Y2 receptor antibodies were then reacted with a
biotinylated goat anti-rabbit antibody (1:200; Vectastain ABC-kit PK-
4001; Vector, Burlingame, CA, USA), togetherwith a peroxidase coupled
horse anti-mouse antibody (1:200; Vector, Burlingame, CA, USA) for de-
tecting β-tubulin or synaptophysin antibodies (120 min, room temper-
ature, as described previously, Wood et al., 2015). The secondary
antibodies were then ﬂuorescence labeled as follows: The horse anti-
mouse antibodies (for synaptophysin or β-tubulin) were reacted with
TSA-Cy3 (1:100; Lumiprobe 21320, purchased through Kerafast, Boston,
MA, USA) 10 min at room temperature followed by labeling of the bio-
tinylated rabbit antibody (Y2 receptors) with streptavidin-coupled Cy5
(Dy Light 649 Streptavidin, Vector; 1:100, 100min at room temperature).
The streptavidin-coupled Cy5 labeling was enhanced by reaction with
tyramide as described previously (Wood et al., 2015). The embedded sec-
tions were analyzed in a ﬂuorescence microscope (TSA-Cy3: Extinction:
548; emission 563; Streptavidin-Cy5: extinction: 655; emission 670).
3. Results
3.1. Distribution of Y2 receptor binding
In agreement with previous reports (Dumont et al., 1996) we ob-
served high concentrations of [125I]PYY3–36 receptor binding in theFig. 1.Effects of kainic acid-induced seizures andof 30 μMGTPγS on [125I]PYY3–36 binding to Y2 r
piriform cortex. In agreementwith previous data on the hippocampus (Roder et al., 1996; Schw
KA-induced seizures (a, d, g) vs. controls (b, e, h) and it was inhibited by 30 μMGTPγS in sectio
PCx, piriform cortex.
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campus (Fig. 1e, h), the stria terminalis (Figs. 1e, h, 2b), the ﬁmbria
(Fig. 2b, d), the piriform cortex (Fig. 1h) and the septum (Figs. 1b, 2b).
Corresponding sections obtained from rats 10 days after a KA-induced
status epilepticus revealed signiﬁcant increases in Y2 receptor binding
in the sectors CA1 and CA3 and in the septum (Fig. 1a, Fig. 2a, e,
Table 1), but not in the stria terminalis (Fig. 1d, g, Fig. 2a, Fig. 3, Table 1).
3.2. Inhibition of PYY3–36 binding by GTPγS is more effective after KA
seizures
Incubation with 30 μM GTPγS revealed a marked (although not en-
tire) reduction in [125I]PYY3–36 binding in all investigated brain areas
(Fig. 1c, f, i, Fig. 2c, g). Respective dose response curves for inhibition
of [125I]PYY3–36 (25 pM) binding by GTPγS are shown for the different
brain areas in Fig. 3. Half maximal inhibitionwas obtained at concentra-
tions between 0.6 μM (hippocampal sector CA3) and 2.3 μM in the sep-
tum(Table 1). Inhibition reachedonly about 75% andwasmaximal at 30
to 100 μM GTPγS. Interestingly, as shown in Figs. 3 and 4, GTPγS was
more effective in inhibiting (the initially increased) [125I]PYY3–36 bind-
ing in sections from KA-treated rats in receptor autoradiographs of the
hippocampal sector CA1 and CA3 and the stria terminalis. The respec-
tive dose response curves revealed clear shifts in sectors CA1 and CA3,
the stria terminalis and the piriform cortex (piriform cortex, statistically
not signiﬁcant) but, interestingly, not in the septum (Fig. 3, Table 1).
3.3. Immunohistochemistry for Y2 receptors
In agreement with the detailed previous description in the mouse
(Stanic et al., 2006) and with our binding data, we observed strongest
Y2-IR in the strata oriens and radiatum of the hippocampal sectors
CA1 and CA3. Labelingwas theremostly diffuse. Nevertheless individual
ﬁbers were seen in the ﬁmbria and stria terminalis with presumed
projections to the septum and bed nucleus of the stria terminalis,eceptors in coronar sections of rats showing the septum, stria terminalis, hippocampus and
arzer et al., 1998) Y2 receptor binding (25 pM [125I]PYY3–36) was increased in all areas after
ns from control rats (c, f, i). Abbreviations: CA3, sector CA3; S, septum; St, stria terminalis;
receptors along axonal ﬁber tracts and its relevance for epilepsy, Neu-
Fig. 2. Y2 receptor binding and immunoreactivity (IR) in horizontal sections at the level of the ventral hippocampus: Effects of kainic acid-induced seizures and of 30 μM GTPγS on
[125I]PYY3–36 binding in the hippocampus, the septum, stria terminalis, and the ﬁmbria. In agreement with previous data on the hippocampus (Roder et al., 1996; Schwarzer et al.,
1998) Y2 receptor binding (25 pM [125I]PYY3–36) was increased in all areas after KA-induced seizures (a, e) and it was inhibited by 30 μM GTPγS in sections from control rats (c, g).
Note the pronounced labeling of the ﬁber tracts of the ﬁmbria and of the stria terminalis (a, b), which is blocked by 30 μM GTPγS (arrows in c). (f) Also labeling of ﬁber tracts of the
Schaffer collaterals in the ventral hippocampus (CA3) was reduced in the presence of GTPγS (g). Panel (d) depicts Y2-IR in the ventral hippocampus (CA1), the septum (S) and the
stria terminalis (St), in (h) ﬁbers in the stria are shown at a larger magniﬁcation. Abbreviations: CA3, sector CA3; S, septum; St, stria terminalis; F, ﬁmbria.
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sumably Schaffer collaterals projecting to sector CA1 at another level,
were seen (not shown). In the KA treated rats, strong labeling of the
dentate hilus and the stratum lucidum was seen, indicating labeling of
mossy ﬁbers.
Y2 receptor autoradiography e.g. in the stria terminalis could also
label receptors on synaptic nerve endings of collaterals of the ﬁbers or
on terminals of innervating neurons. We therefore performed double-
immunoﬂuorescence labeling of Y2 receptors with β-tubulin, a marker
for axonal tracts, and with synaptophysin, labeling synaptic terminals
(Fig. 5). Whereas β-tubulin-IR co-labeled Y2-containing ﬁbers
(Fig. 5a–c), we observed no co-existence of synaptophysin with Y2
(Fig. 5d–f). Taken together, these data strongly support the idea that
Y2 receptors are not only located on nerve terminal but also along
ﬁber tracts.
4. Discussion
Herewe showdose-dependent inhibition of [125I]PYY3–36 binding by
GTPγS demonstrating functional coupling of Y2 receptors to G-proteins.
The inhibition of [125I]PYY3–36 binding is thought to result from aTable 1
IC50 values for inhibition of [125I]PYY3–36 binding (25 pM) by GTPγS and the increase in [125
Schwarzer et al., 1998)). The data represent the mean of three rats (mean of three sections pe
GTPγS IC50 (μM ± SEM)
Control KA
CA3 2.6 ± 0.20 0.6 ±
Stria terminalis 3.2 ± 0.25 1.9 ±
Piriform cortex 4.1 ± 1.01 1.9 ±
Septum 2.8 ± 0.68 2.3 ±
ns, not signiﬁcant.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.
Please cite this article as: Dum, E., et al., Effective G-protein coupling of Y2
ropeptides (2016), http://dx.doi.org/10.1016/j.npep.2016.10.005decreased afﬁnity of the receptor to the respective ligand in the pres-
ence of non-hydrolysable GTPγS (Parker et al., 2007a). The major ﬁnd-
ings of the present study are: 1) [125I]PYY3–36 binding is more sensitive
to GTPγS in sector CA1, the stria terminalis and (statistically not signif-
icant) the piriform cortex from rats after KA-induced seizures, suggest-
ing altered coupling to G-proteins. 2) [125I]PYY3–36 binding is associated
with typical ﬁber tracts such as Schaffer collaterals, the ﬁmbria and the
stria terminalis, and is there sensitive to GTPγS, indicating that Y2 re-
ceptors expressed along these ﬁber tracts are functionally coupled to
G-proteins.
An obvious uncertainty of this conclusion is that most of the ﬁber
tracts could contain either collateral nerve terminals or synapses of
innervating NPY containing neurons. This is certainly the case in hip-
pocampal sectors CA1 and CA3 where Schaffer collaterals and the
piriform cortex impinge on pyramidal cell dendrites. Thus the bind-
ing data in these regions may reﬂect a mixture of axon tracts and
axon terminals. Our immunohistochemical data in the ﬁmbria, how-
ever, indicate that there Y2 receptors are primarily located upon
ﬁber tracts. Y2-immunoreactivity is mainly associated with the axo-
nal marker β-tubulin but not synaptophysin, a marker for nerve
terminals.I]PYY3–36 binding (25 pM) without GTPγS (see our previous studies (Roder et al., 1996;
r rat). Statistics were done by Student's t-test.
Change in total binding (% of control ± SEM)
0.16⁎⁎ 189 ± 17.8⁎⁎⁎
0.30⁎ 103 ± 0.3 n.s.
0.86 n.s 155 ± 16.8⁎⁎
0.98 n.s 262 ± 17.8⁎⁎
receptors along axonal ﬁber tracts and its relevance for epilepsy, Neu-
Fig. 3.Dose response curves for GTPγS on [125I]PYY3–36 binding (25 pM). Shown are (a) the stratumoriens of hippocampal sector CA3 (similar resultswere obtained in sector CA1), (b) the
stria terminalis, (c) the piriform cortex and (d) the septum. Data show mean [125I]PYY3–36 binding ± SEM for each GTPγS concentration (0.1, 1.0, 3.0, 10.0, 30.0, 100 μM). In CA3
concentrations of 0.03, 0.3, 300 and 1000 μM were also examined. Each point represents the mean of three animals (mean of three sections per rat). IC50 values and statistics are
shown in Table 1.
Fig. 4. Images of [125I]PYY3–36 receptor binding in sections containing theAmmon's horn (sectors CA1 and CA3), theﬁmbria and the stria terminalis incubated at different concentrations of
GTPγS. Panel (a) shows bright ﬁeld photomicrographs from KA treated and control rats, panel (b) shows the same images in pseudo colors. The increase in Y2 receptor binding after KA is
best seen in the pseudo color images.
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Fig. 5.Double immunoﬂuorescence labeling of Y2 receptors in the stria terminalis with β-tubulin and synaptophysin. Panels a–c show labeling of the stria terminalis in coronary sections
for β-tubulin, amarker for axons. It co-labels with Y2-IR (b and c). In contrast synaptophysin-IR does not coexist with Y2-IR (d–f). The data indicate that Y2-IR is contained at axonal ﬁbers
and not at collaterals containing synapses.
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At the low concentration used (25 pM) [125I]PYY3–36 rather selec-
tively labels Y2 receptors (Dumont et al., 1996; El Bahh et al., 2005).
Y2 receptors are Gi/q-protein coupled receptors presumably inhibiting
voltage-dependent N-type Ca2+ channels or activating inwardly recti-
fying (GIRK) K+ channels (Herzog et al., 1992; Sun et al., 1998; Parker
et al., 2007b). Functional coupling of G-proteins with Y2 receptors has
been elegantly shown by activation of [35S]GTPγS binding by Y2 ago-
nists (Primus et al., 1998; Shaw et al., 2003; Christensen et al., 2006). In-
terestingly GTPγS inhibits [125I]PYY3–36 only byup to 75%. It is likely that
the remaining component represents binding to spare receptors (locat-
ed in themembrane or in the cytoplasm) that are not yet coupled to G-
proteins.4.2. The effects of GTPγS on [125I]PYY3–36 binding
Our present observation that Y2 receptor binding is increased in ep-
ileptic rats is in agreement with our previous data using receptor auto-
radiography and in situ hybridization in the same animal model (Roder
et al., 1996; Gobbi et al., 1998; Schwarzer et al., 1998).We had observed
a rapid increase in afﬁnity of Y2 receptors (notably in hippocampal sec-
tor CA1) followed by increased mRNA expression in dentate granule
cells (Schwarzer et al., 1998). Both mechanisms may facilitate NPY
transmission at Y2 receptors and thus presynaptic inhibition of gluta-
mate release from respective neurons. As discussed before, this may
represent an endogenous mechanism ameliorating or terminating epi-
leptic seizures (Marksteiner et al., 1990; Sperk et al., 1992; Roder
et al., 1996; Schwarzer et al., 1998; Vezzani et al., 1999; Drexel et al.,
2012). It is interesting to note that, in contrast to thehippocampal sector
CA1, the septum and the piriform cortex, Y2 receptor binding was not
increased in the stria terminalis of KA treated rats. A possible explana-
tion for this may be that the stria terminalis contains primarily GABA-
ergic projection neurons (Le Gal LaSalle et al., 1978) whereas in the sec-
tor CA1 and in the piriform cortex Y2 receptors are presumably located
on glutamatergic neurons.
The decrease in IC50 for inhibition of Y2 receptor binding byGTPγS is
indicative for facilitated G-protein coupling in the epileptic rats. Also
such a mechanism may support transmission through the respectivePlease cite this article as: Dum, E., et al., Effective G-protein coupling of Y2
ropeptides (2016), http://dx.doi.org/10.1016/j.npep.2016.10.005receptors. Interestingly, daily treatment of rats with electroconvulsive
shocks for 14 days failed to alter NPY-stimulated [35S]GTPγS binding
in the dentate gyrus, hippocampal sector CA1, and neocortex
(Christensen et al., 2006). In variance with our data on increased Y2 re-
ceptor binding in the kainate model, the authors observed in the same
brain areas also decreased NPY sensitive binding in spite of increased
Y2 receptor mRNA levels in the electroconvulsive shock model. These
discrepancies between functional NPY stimulated [35S]GTPγS binding
and their in situ hybridization data and our data in the KA model may
in part be explained by the fact that Christensen et al. (2006) used
NPY for stimulation of [35S]GTPγS (affecting all receptor subtypes),
whereas we investigated the effect of GTPγS on Y2-speciﬁc
[125I]PYY3–36 binding taking into account the differential regulation of
Y1 and Y2 receptors after seizures. Thus, in contrast to Y2 receptors,
Y1 receptors are down-regulated on granule cell dendrites in the KA
model, presumably due to internalization (Koﬂer et al., 1997). Further-
more, repeated electroconvulsive stimulation used by Christensen et al.
(2006) may activate the NPY system differently than the severe but
transient status epilepticus in our model.4.3. Fiber tracts of the stria terminalis and ﬁmbria contain functionally
coupled Y2 receptors
More importantly, our data show that Y2-selective [125I]PYY3–36
binding is not only present on ﬁber tracts like the Schaffer collaterals,
the stria terminalis and the ﬁmbria, but that it is also regulated there
by GTPγS. To demonstrate this, we used horizontal brain sections, in
which the ﬁmbria and the stria terminalis are presented as clear ﬁber
tracts presumably without axon terminals (see Fig. 2 h). Inhibition of
[125I]PYY3–36 binding by GTPγS in the stria terminalis and the ﬁmbria,
however, indicates that Y2 receptors are G-protein coupled, thus func-
tional, along these ﬁber tracts. In contrast, GTPγS-coupled Y2 receptors
in the terminal area of Schaffer collaterals of CA3 and CA1 may not only
label the ﬁber tract but also the respective axon terminals impinging on
CA1 pyramidal cell dendrites. In case of the stria terminalis this was ex-
cluded by the fact that the axonal marker β-tubulin co-existed with Y-
receptors, but not the synaptic marker synaptophysin. This clearly indi-
cates that Y2 receptors along the stria terminalis are located on the ax-
onal tract and not at nerve terminals.receptors along axonal ﬁber tracts and its relevance for epilepsy, Neu-
7E. Dum et al. / Neuropeptides xxx (2016) xxx–xxxAn obvious question that arises is, which function do the Y2 recep-
tors along axon collaterals have and how does NPY reach Y2 receptors
far away from the site of NPY release?WhereasNPY ismainly contained
in GABA and noradrenaline neurons, Y2 receptors are also located on
glutamatergic neurons in addition to GABA containing terminals
(Stanic et al., 2006). Theymediate inhibition of release of the respective
neurotransmitters (Martire et al., 1993; Greber et al., 1994; Klapstein
and Colmers, 1997; Sun et al., 2001). Thus, at least in the case of gluta-
mate neurons, NPY has to reach its Y2 receptors by volume transmis-
sion. The afﬁnity of Y2 receptors as revealed by receptor binding is
high (KD around 50 pM in the hippocampus), (Dumont et al., 1995). It
is therefore feasible that Y2 receptors located along axonal ﬁber tracts
are activated even after dilution of NPY by its distantmigration. Further-
more, our recent ﬁnding that NPY-expressing neurons are also located
within long ﬁber tracts, such as the stria terminalis, suggests that Y2 re-
ceptor containing long-range projections can be modulated along ﬁber
tracts (Wood et al., 2015). KA-induced seizures increase the afﬁnity of
Y2 receptors to Schaffer collateral terminals (Schwarzer et al., 1998)
and glutamate release is inhibited (decrease of the KD for NPY in
inhibiting glutamate release) (Greber et al., 1994; Schwarzer et al.,
1998).
Taken together, our data suggest that ﬁber tracts like the ﬁmbria, the
stria terminalis and the Schaffer collaterals contain Y2 receptors that are
coupled to G-proteins and thus may be functionally active. This is sup-
ported by the facts that [125I]PYY3–36 binding is increased and the IC50
value for GTPγS in inhibiting [125I]PYY3–36 binding is lowered in the hip-
pocampal sector CA1 and in the piriform cortex of KA treated rats.
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